Compare MSTR & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSTR | NTRA |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4B | 56.7B |
| IPO Year | 1998 | 2015 |
| Metric | MSTR | NTRA |
|---|---|---|
| Price | $86.12 | $289.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 23 |
| Target Price | $233.27 | ★ $412.36 |
| AVG Volume (30 Days) | ★ 13.2M | 1.9M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $463,456,000.00 | $210,939,000.00 |
| Revenue This Year | $4.81 | $30.72 |
| Revenue Next Year | $3.06 | $21.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $81.81 | $181.00 |
| 52 Week High | $198.40 | $437.41 |
| Indicator | MSTR | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 21.95 | 27.42 |
| Support Level | N/A | $189.54 |
| Resistance Level | $104.96 | $334.60 |
| Average True Range (ATR) | 7.39 | 20.82 |
| MACD | -4.40 | -8.12 |
| Stochastic Oscillator | 1.48 | 8.36 |
Strategy Inc is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provides industry AI-powered enterprise analytics software. It has one reportable operating segment: the Software Business, which is engaged in the design, development, marketing, and sales of the company's enterprise analytics software platform through cloud subscriptions and licensing arrangements and related services (i.e., product support, consulting, and education). Geographically, the company operates in EMEA, U.S. and Other Regions, of which maximum revenue is derived from U.S..
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.